TLS data
 

Events and Networking

Expand Your Network at One of Biocom’s 150+ Annual Events

Partner Day with Novo Nordisk

When:

Tue Nov 20 01:00:00 GMT 2018 - Tue Nov 20 03:00:00 GMT 2018

Where:

The Illumina Theatre at The Alexandria
10996 Torreyana Road
San Diego, CA 92121

Register

November 19th, senior leaders from Novo Nordisk will be in San Diego to meet with local biotech companies,  academic institutions, research organizations, venture capital firms, and the local San Diego Life Sciences community. Throughout the day, Novo Nordisk  will cover their therapeutic areas of focus for innovation partnering along with an interactive panel discussion. A complimentary networking reception will follow the program.

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone related disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries.

The Mission of Novo Nordisk R&D is to develop innovative therapeutic proteins for chronic illnesses. Scientific collaborations with strategic partners in industry and academia are essential part of this pursuit for sustainable innovation. In addition, Novo Nordisk explores commercial partnerships on a global scale to bring innovative therapies to patients.

Partner Day Agenda

  • 5:00pm – 5:30pm: Networking & Registration
  • 5:30pm – 5:45pm Novo Nordisk Corporate Overview & Brief Presentation 
    • Welcome 
    • Corporate Overview
    • Therapeutic Area Overview
    • Partnering with Novo Nordisk
  • 5:45pm – 7:00pm: Networking Reception
 
Areas of Focus:


Diabetes:
  • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
  • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
  • Compounds that have improved effects on Beta cell health
  • Oral peptides and novel protein delivery platforms
  • Novel approaches to treating Type I Diabetes
Obesity:
  • Novel compounds that effect appetite regulation and energy expenditure
  • Novel compounds that show improvement in lean body mass through fat loss
  • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
  • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%
 
Other Chronic Diseases:
  • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
  • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
  • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
  • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
  • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches
 
Other Focus Areas:
  • Cell therapies (stem cells), differentiation protocols for chronic series diseases
  • Novel cell encapsulation technologies
  • Platforms for RNA-based therapies
  • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
  • Exosomes and other cell penetrating technologies

In Partnership With: 

User-added image

 

Price of Admission

Biocom Member/Non-Member

Today's Price: 0.0

Important Dates

Amount

Registration before

Registration before

Registration before

0.0

Refund before Mon Nov 19 00:00:00 GMT 2018

0.0

Refund before

Refund Before

*Refunds will no longer be accepted after

  • Areas of Interest

    Diabetes

    • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
    • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
    • Compounds that have improved effects on Beta cell health
    • Oral peptides and novel protein delivery platforms
    • Novel approaches to treating Type I Diabetes
     

    Obesity
    • Novel compounds that effect appetite regulation and energy expenditure
    • Novel compounds that show improvement in lean body mass through fat loss
    • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
    • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%
     
    Other Chronic Diseases
    • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
    • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
    • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
    • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
    • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches
     
    Other Focus Areas
    • Cell therapies (stem cells), differentiation protocols for chronic series diseases
    • Novel cell encapsulation technologies
    • Platforms for RNA-based therapies
    • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
    • Exosomes and other cell penetrating technologies
    a0d5A00000KLGbyQAH

    Go
  • Agenda

    Partner Day Agenda

    • 5:00pm – 5:30pm: Networking & Registration
    • 5:30pm – 5:45pm Novo Nordisk Corporate Overview & Brief Presentation 
      • Welcome 
      • Corporate Overview
      • Therapeutic Area Overview
      • Partnering with Novo Nordisk
    • 5:45pm – 7:00pm: Networking Reception

    a0d5A00000KLGboQAH
    Go
  • Areas of Interest

    Diabetes

    • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
    • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
    • Compounds that have improved effects on Beta cell health
    • Oral peptides and novel protein delivery platforms
    • Novel approaches to treating Type I Diabetes
     

    Obesity
    • Novel compounds that effect appetite regulation and energy expenditure
    • Novel compounds that show improvement in lean body mass through fat loss
    • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
    • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%
     
    Other Chronic Diseases
    • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
    • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
    • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
    • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
    • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches
     
    Other Focus Areas
    • Cell therapies (stem cells), differentiation protocols for chronic series diseases
    • Novel cell encapsulation technologies
    • Platforms for RNA-based therapies
    • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
    • Exosomes and other cell penetrating technologies
    a0d5A00000KLGbyQAH

    Go
  • Apply - 1:1 Meeting

    One-on-One Meeting Opportunity:

    If you are working in any of the areas of interest outlined above please submit a one page company overview including detailed descriptions of any program(s) you would like to discuss to Oscar Rodarte at orodarte@biocom.org as soon as possible, but no later, than Friday, October 19th for consideration.

    a0d5A00000KLGbtQAH
    Go
  • Areas of Interest

    Diabetes

    • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
    • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
    • Compounds that have improved effects on Beta cell health
    • Oral peptides and novel protein delivery platforms
    • Novel approaches to treating Type I Diabetes
     

    Obesity
    • Novel compounds that effect appetite regulation and energy expenditure
    • Novel compounds that show improvement in lean body mass through fat loss
    • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
    • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%
     
    Other Chronic Diseases
    • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
    • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
    • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
    • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
    • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches
     
    Other Focus Areas
    • Cell therapies (stem cells), differentiation protocols for chronic series diseases
    • Novel cell encapsulation technologies
    • Platforms for RNA-based therapies
    • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
    • Exosomes and other cell penetrating technologies
    a0d5A00000KLGbyQAH

    Go
  • Areas of Interest

    Diabetes

    • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
    • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
    • Compounds that have improved effects on Beta cell health
    • Oral peptides and novel protein delivery platforms
    • Novel approaches to treating Type I Diabetes
     

    Obesity
    • Novel compounds that effect appetite regulation and energy expenditure
    • Novel compounds that show improvement in lean body mass through fat loss
    • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
    • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%
     
    Other Chronic Diseases
    • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
    • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
    • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
    • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
    • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches
     
    Other Focus Areas
    • Cell therapies (stem cells), differentiation protocols for chronic series diseases
    • Novel cell encapsulation technologies
    • Platforms for RNA-based therapies
    • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
    • Exosomes and other cell penetrating technologies

    a0d5A00000KLGbyQAH
    Go

Register